Background: Mutations in the PINK1 gene, encoding a mitochondrial protein kinase, represent the second cause of autosomal recessive parkinsonism (ARP) after Parkin. While homozygous or compound heterozygous mutations in these genes are unequivocally causative of ARP, the role of single heterozygous mutations is still largely debated. An intriguing hypothesis suggests that these mutations could represent a risk factor to develop parkinsonism, by contributing to nigral cell degeneration. Since the substantia nigra plays an important role in temporal processing of sensory stimuli, as revealed from studies in idiopathic PD, we sought to investigate whether any subclinical sensory abnormalities could be detected in patients with PINK1- related parkinsonism and in unaffected PINK1 heterozygous carriers.
Methods: We adopted a psychophysical method, the temporal discrimination paradigm, to assess PINK1 homozygous patients, unaffected relatives who were heterozygous carriers of the same mutations and healthy control subjects. Temporal discrimination threshold (TDT) and temporal order judgement (TOJ) for pairs of tactile, visual or visuo-tactile stimuli were measured according to a standardized protocol.
Findings: Higher mean tactile and visuo-tactile TDTs and TOJs were detected in PINK1 mutation carriers, including not only homozygous patients but also healthy heterozygotes, compared to control subjects (for all comparisons, p < 0.001).
Interpretation: In clinically unaffected subjects, the mere presence of a heterozygous PINK1 mutation is sufficient to determine sensory alterations which can be disclosed by a psychophysical task. Deficits in temporal processing might be considered as subclinical signs of alteration at least in PINK1-related parkinsonism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00415-008-0923-6 | DOI Listing |
Am J Gastroenterol
December 2024
Gastroenterology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
This study investigates whether subclinical inflammation in asymptomatic inflammatory bowel disease (IBD) patients leads to increased medication use. In a multicenter, retrospective analysis of patients diagnosed with incidental ulcerative colitis or Crohn's disease during colorectal cancer screening (2010-2021), medication use was compared with symptomatic patients and healthy non-IBD controls. Asymptomatic patients showed a higher use of cardiovascular, antiparasitic, musculoskeletal, respiratory, and sensory organ medications up to five years before diagnosis.
View Article and Find Full Text PDFBrain Sci
October 2024
Faculty of Health Sciences, Ontario Tech University, Oshawa, ON L1G 0C5, Canada.
Background/objectives: Sensorimotor dysfunction is often reported in individuals experiencing neck pain, irrespective of severity and chronicity. The treatment of neck dysfunction has been found to positively impact sensorimotor integration (SMI), thereby improving sensorimotor function. However, no patient-reported outcome measure has been validated for discrimination between healthy individuals and neck pain patients with disordered SMI, nor has there been documentation of positive change in SMI following neck pain treatment.
View Article and Find Full Text PDFNeurol Neurochir Pol
December 2024
Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic.
Aim Of Study: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG.
Clinical Rationale For Study: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment.
Prog Neuropsychopharmacol Biol Psychiatry
October 2024
Mental Health Research Center, 34 Kashirskoye Sh, Moscow 115522, Russian Federation.
Epilepsia Open
December 2024
Department of Neuroscience, Corewell Health, Grand Rapids, Michigan, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!